New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease

@article{Sahebkar2014NewPP,
  title={New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease},
  author={Amirhossein Sahebkar and Gerard T. Chew and Gerald F. Watts},
  journal={Expert Opinion on Pharmacotherapy},
  year={2014},
  volume={15},
  pages={493 - 503}
}
Introduction: Novel peroxisome proliferator-activated receptor (PPAR) modulators (selective PPAR modulators [SPPARMs]) and dual PPAR agonists may have an important role in the treatment of cardiometabolic disorders owing to lipid-modifying, insulin-sensitizing and anti-inflammatory effects. Areas covered: This review summarizes the efficacy of new PPAR agonists and SPPARMs that are under development for the treatment of atherogenic dyslipidemia and non-alcoholic fatty liver disease (NAFLD… 
Early investigational drugs targeting PPAR-α for the treatment of metabolic disease
TLDR
The highly potent and selective PPar-α agonist K-877 has shown beneficial effects on atherogenic dyslipidemia and absence of some adverse effects seen with fibrates, and the dual PPAR-α/PPAR-δ agonist GFT-505 appears to be a potential candidate for the treatment of NAFLD.
Targeting Peroxisome Proliferator-activated Receptor delta (PPARδ): A Medicinal Chemistry Perspective.
TLDR
The challenges of PPARδ selectivity and the medicinal chemistry of most active agonists discovered by different pharmaceutical companies and institutes are focused on.
PPAR Agonists and Metabolic Syndrome: An Established Role?
TLDR
The PPAR system thus offers an important hope in the management of atherogenic dyslipidemias, although concerns regarding potential adverse events such as the rise of plasma creatinine, gallstone formation, drug–drug interactions, and myopathy should also be acknowledged.
The Role of PPAR-δ in Metabolism, Inflammation, and Cancer: Many Characters of a Critical Transcription Factor
TLDR
The complex relationship between PPAR-δ in health and disease is discussed and the current knowledge regarding the different roles that PPAR -δ plays in metabolism, inflammation, and cancer is highlighted.
Molecular Actions of PPARα in Lipid Metabolism and Inflammation.
TLDR
The full potential of this nuclear receptor subtype as a versatile drug target with high plasticity becomes increasingly clear, and a novel generation of agonists may pave the way for novel fields of applications.
Unraveling the Effects of PPARβ/δ on Insulin Resistance and Cardiovascular Disease
Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence
TLDR
The future design of better PPAR modulators with minimal off-target effects, high selectivity, superior bioavailability, and pharmacokinetics are anticipated, which will open new possibilities for PPAR ligands in medicine.
PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part II: PPAR-β/δ and PPAR-γ.
TLDR
The aim of this review is to provide up-to-date information about the biochemical and metabolic actions of PPAR-β/δ andPPAR-γ, the therapeutic potential of their agonists currently under clinical development and the cardiovascular disease outcome of clinical trials of PPar-γ agonists, pioglitazone and rosig litazone.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 82 REFERENCES
Selective peroxisome proliferator-activated receptorα modulators (SPPARMα): The next generation of peroxisome proliferator-activated receptor α-agonists
TLDR
Compared to fenofibrate, K-877 has more potent PPARα-activating efficacy in vitro, greater effects on triglycerides- and HDL-C levels in humans, and a reduced risk of adverse effects.
Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors
TLDR
A more precise understanding of the molecular pathways implicated in the response to chemically distinct PPAR agonists should provide new opportunities for targeted therapeutic applications in the management of the metabolic syndrome, type 2 diabetes, and cardiovascular diseases.
Selective peroxisome proliferator-activated receptor-γ modulation to reduce cardiovascular risk in patients with insulin resistance.
TLDR
Early phase human studies with INT131 look promising with changes in plasma lipids and glucose being equal or better than what is seen with rosig litazone and pioglitazone treatment but without evidence of edema.
Safety issues and prospects for future generations of PPAR modulators.
Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity.
TLDR
The mechanism of action of this PPAR-δ agonist on lipoprotein metabolism is elucidated and supports its potential use in treating dyslipidemia in obesity.
MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin.
TLDR
MBX-8025, a novel PPAR-δ agonist, favorably affected multiple metabolic parameters with and without atorvastatin and was safe and generally well-tolerated.
Peroxisome proliferator-activated receptor &dgr;: a multifaceted metabolic player
TLDR
Progresses in the understanding of PPAR&dgr; reveal that activation of this receptor represents a multifaceted therapeutic strategy for the prevention and treatment of insulin-resistant syndromes and atherosclerosis.
Diabetes: New conductors for the peroxisome proliferator-activated receptor γ (PPARγ) orchestra.
  • J. Whitehead
  • Biology, Chemistry
    The international journal of biochemistry & cell biology
  • 2011
Activation of Peroxisome Proliferator–Activated Receptor (PPAR)δ Promotes Reversal of Multiple Metabolic Abnormalities, Reduces Oxidative Stress, and Increases Fatty Acid Oxidation in Moderately Obese Men
TLDR
The PPARδ agonist GW501516 reverses multiple abnormalities associated with the metabolic syndrome without increasing oxidative stress and is probably caused by increased fat oxidation in skeletal muscle.
...
1
2
3
4
5
...